Considering Valproate as a Risk Factor for Rapid Exacerbation of Complex Movement Disorder in Progressed Stages of Late-Infantile CLN2 Disease

Abstract

Neuronal ceroid lipofuscinosis type 2 (CLN2 disease, OMIM 204500) is a rare autosomal-recessive lysosomal storage disorder. It is one of the most common neurodegenerative disorders in childhood. Symptoms include epilepsy, rapid motor and language regression, dementia, visual loss, and a complex movement disorder in later stages of the disease. We report on two children with genetically confirmed late-infantile CLN2 disease who developed a severe exacerbation of their complex movement disorder leading to hyperthermia, hyper-CK-emia and decreased level of consciousness over several weeks despite different therapeutic approaches. Both patients were on long-term antiepileptic treatment with valproate and only after the withdrawal of valproate, the movement disorder disappeared and level of consciousness improved. These observations emphasize that valproate has to be considered as a possible risk factor in patients in later stages of late-infantile CLN2 disease who develop a rapidly progressive complex movement disorder.

Keywords

late-infantile CLN2 disease - valproate - exacerbation of movement disorder

^* The authors Jessika Johannsen and Miriam Nickel contributed equally to the article.

• References

• 1 Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R. NCL diseases - clinical perspectives. Biochim Biophys Acta 2013; 1832 (11) 1801-1806
• 2 Sleat DE, Donnelly RJ, Lackland H , et al. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 1997; 277 (5333) 1802-1805
• 3 Schulz A, Nickel M, Downs M , et al. O62–1673 The natural history of late infantile CLN2 disease: striking homogeneity of clinical progression in two independently obtained large clinical cohorts. Eur J Paediatr Neurol 2013; 17: S20
• 4 Naidu S. Movement disorders in neuronal ceroid-lipofuscinoses. J Inherit Metab Dis 1993; 16 (2) 256-258
• 5 Kipps CM, Fung VS, Grattan-Smith P, de Moore GM, Morris JG. Movement disorder emergencies. Mov Disord 2005; 20 (3) 322-334
• 6 Allen NM, Lin JP, Lynch T, King MD. Status dystonicus: a practice guide. Dev Med Child Neurol 2014; 56 (2) 105-112
• 7 Gerstner T, Bell N, König S. Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Expert Opin Pharmacother 2008; 9 (2) 285-292
• 8 Zadikoff C, Munhoz RP, Asante AN , et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 2007; 78 (2) 147-151
• 9 Chopra A, Kolla BP, Mansukhani MP, Netzel P, Frye MA. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. Gen Hosp Psychiatry 2012; 34 (3) 290-298
• 10 Gerstner T, Buesing D, Longin E , et al. Valproic acid induced encephalopathy—19 new cases in Germany from 1994 to 2003—a side effect associated to VPA-therapy not only in young children. Seizure 2006; 15 (6) 443-448
• 11 Elkay M, Silver K, Penn RD, Dalvi A. Dystonic storm due to Batten's disease treated with pallidotomy and deep brain stimulation. Mov Disord 2009; 24 (7) 1048-1053
• 12 Larsen EP, Østergaard JR. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease). Seizure 2014; 23 (6) 429-434
• 13 Quartarone A, Rizzo V, Morgante F. Clinical features of dystonia: a pathophysiological revisitation. Curr Opin Neurol 2008; 21 (4) 484-490
• 14 Alvarez-Gomez MJ, Vaamonde J, Narbona J , et al. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol 1993; 16 (5) 451-455
• 15 Palmer DN, Barry LA, Tyynelä J, Cooper JD. NCL disease mechanisms. Biochim Biophys Acta 2013; 1832 (11) 1882-1893